CALIMMUNE

calimmune-logo

Calimmune is a clinical-stage gene therapy company. The company’s lead therapeutic candidate, is a gene-based therapy engineered to control HIV infection and to protect individuals with HIV from progressing to AIDS. The therapy is currently being evaluated in Phase I/II studies. Cal-1 is designed to reduce production of CCR5, a protein on the surface of white blood cells that plays a critical role in enabling HIV to infect cells. It also has a second mechanism aimed at preventing viral fusion, the process by which the virus enters the cell. This dual approach was shown to be effective against broad strains of HIV in pre-clinical studies.

#SimilarOrganizations #People #Financial #Website #More

CALIMMUNE

Industry:
Biotechnology Genetics Health Care Medical Therapeutics

Founded:
2006-01-01

Address:
Pasadena, California, United States

Country:
United States

Website Url:
http://www.calimmune.com

Total Employee:
1+

Status:
Active

Contact:
(619) 849-5375

Email Addresses:
[email protected]

Total Funding:
15.85 M USD

Technology used in webpage:
Viewport Meta Font Awesome Mobile Non Scaleable Content Pound Sterling Starfield Technologies Sucuri Cloudproxy ATT DNS


Similar Organizations

acasti-pharma-logo

Acasti Pharma

Acasti Pharma is an emerging biopharmaceutical company.

atara-biotherapeutics-logo

Atara Biotherapeutics

Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.

birchbiomed-logo

BirchBioMed

BirchBioMed is a clinical-stage biomedical company.

bolder-biotechnology-logo

Bolder BioTechnology

Bolder BioTechnology, Inc. is a clinical stage protein therapeutics company.

cellenkos-logo

Cellenkos

Cellenkos is a clinical stage biotech company.

cure-forward-logo

Cure Forward

Cure Forward helps cancer patients and physicians access advanced treatments in oncology.

giiant-pharma-logo

Giiant Pharma

Giiant Pharma is a preclinical-stage biotech company.

juno-therapeutics-logo

Juno Therapeutics

Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.

olix-pharmaceuticals-logo

OliX Pharmaceuticals

OliX is a clinical stage biotechnology company.

rain-therapeutics-logo

Rain Therapeutics

Rain Therapeutics is a operator of a clinical stage biotechnology company.

rion-logo

Rion

RION is a clinical-stage regenerative medicine company.

sirenas-marine-discovery-logo

Sirenas Marine Discovery

A Biomedical research organization

virometix-logo

Virometix

Virometix is a privately held biotechnology company developing

wegene-logo

WeGene

WeGene is a genetic testing and personalized healthcare service provider company.

caredx-logo

CareDx

CareDx is a novel mol­e­c­u­lar diagnos­tics com­pany.


Current Advisors List

david-baltimore_image

David Baltimore Chairman of the Board of Directors @ Calimmune
Board_member
2008-01-01

Current Employees Featured

not_available_image

Louis Breton
Louis Breton Co-Founder & Chief Executive Officer @ Calimmune
Co-Founder & Chief Executive Officer

david-baltimore_image

David Baltimore
David Baltimore Co-Founder @ Calimmune
Co-Founder
2008-01-01

Founder


david-baltimore_image

David Baltimore

not_available_image

Louis Breton

Investors List

alexandria-venture_image

Alexandria Venture

Alexandria Venture investment in Series B - Calimmune

translational-accelerator-llc_image

Translational Accelerator

Translational Accelerator investment in Series B - Calimmune

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - Calimmune

Official Site Inspections

http://www.calimmune.com

  • Host name: cloudproxy10005.sucuri.net
  • IP address: 192.124.249.5
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Calimmune"

Calimmune - Crunchbase Company Profile & Funding

May 27, 2015 Calimmune may be growing as indicated by the sale of the company to CSL Behring, which suggests a successful exit and a likely increase in resources and capabilities. The company's leadership, consisting of …See details»

CSL Behring Acquires Biotech Company Calimmune and its …

About Calimmune: Calimmune is a privately owned company committed to accelerating the promise of gene therapy to liberate patients from chronic and currently incurable diseases. To …See details»

Calimmune Company Profile 2024: Valuation, Investors …

Calimmune General Information Description. Developer of a gene modification and cell delivery technology based in Tucson, Arizona. The company's technology works by genetically modifying patients' own cells to shield and strengthen …See details»

CSL Behring to Acquire Biotech Company Calimmune …

CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform. Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Calimmune, Inc., a …See details»

CSL Behring buys Calimmune for early stem cell, gene …

Aug 28, 2017 Calimmune’s chief, Louis Breton, added: “We are excited to become part of CSL Behring. They are an established global industry leader in protein-replacement therapies and have a proven track ...See details»

CALIMMUNE, INC. Company Profile | Pasadena, CA | Competitors ...

Find company research, competitor information, contact details & financial data for CALIMMUNE, INC. of Pasadena, CA. Get the latest business insights from Dun & Bradstreet.See details»

Calimmune, Inc. - LinkedIn

Calimmune, Inc. | 736 followers on LinkedIn. Calimmune was founded in 2006 based on breakthrough gene modification and cell delivery technology developed in the labs of Nobel Laureate David ...See details»

CSL Behring pays $91M upfront for early stage gene therapy

Aug 30, 2017 CSL Behring has bought out Calimmune, a Tucson-based stem cell gene therapy biotech, for a $91 million upfront payment. The deal gives CSL Behring access to …See details»

Tucson's Calimmune to be acquired by Australian drug giant

Aug 29, 2017 Calimmune Inc., a gene-therapy drug startup company co-founded by a University of Arizona alumnus, will be acquired by Australian-based biotech drug giant CSL Ltd. for $91 …See details»

Expanding Cell- and Gene-Therapy Capability in the …

The original lab and office space at the Hill site became part of CSL Behring in 2017 upon the acquisition of Calimmune Inc. From 2018 to 2019, the Good Manufacturing Practice (GMP) cell manufacturing facility and two additional …See details»

CSL Behring to Acquire Biotech Company Calimmune …

Aug 28, 2017 Calimmune's lead development programs are novel ex vivo gene therapies for hematologic diseases. About CSL Behring CSL Behring is a global biotherapeutics leader driven by its promise to save lives.See details»

Calimmune - Products, Competitors, Financials, Employees, …

Calimmune is developing a full product pipeline of therapeutic candidates to address the unique needs of individuals at different stages of HIV infection and with various treatment histories. …See details»

CSL buys stem cell therapy firm Calimmune | SBS News

Aug 28, 2017 The acquisition will provide CSL Behring, CSL's blood products business, with Calimmune's haematopoietic stem cell gene therapy which is being developed for the …See details»

Calimmune - VentureRadar

Calimmune's lead product candidate for HIV, now in Phase I/II studies, is being evaluated as a one-time treatment to prevent HIV progression to AIDS. Calimmune is developing a full …See details»

Sickle Cell Disease Therapies May Get Boost from CSL Behring's...

Sep 7, 2017 Calimmune “has built a robust technology platform, and designed a promising HSC gene therapy candidate, CAL-H, which strongly aligns with our longer-term strategic goals, …See details»

The Arizona Bioscience Company of the Year is on a Mission to …

Calimmune, Inc., acquired by global biotechnology leader CSL Limited in 2017 and now fully integrated within CSL, to be honored as the Arizona Bioscience Company of the Year at the …See details»

HIV biotech Calimmune bags $15M to move one-time gene

May 27, 2015 After getting started 9 years ago with backing from angel investors, Calimmune just landed a $15 million B round, positioning the biotech to move into the clinic with a gene …See details»

Calimmune Approved to Treat Second Group in HIV Stem Cell …

Calimmune is a clinical-stage HIV gene medicine company focused on developing innovative cell-based therapies for HIV. The company’s stem cell technology was discovered in the labs of …See details»

Calimmune Expands Lentiviral Gene Therapy Pipeline Through

Dec 5, 2016 TUCSON, Ariz.--(BUSINESS WIRE)--Calimmune, Inc., a clinical-stage gene therapy company, today announced a license agreement with Cincinnati Children’s Hospital …See details»

CalImmune Cleared to Move HIV Drug into Next Cohort in Phase …

Jul 3, 2014 CalImmune was founded to develop a method for preventing HIV infection from progressing to AIDS by knocking down CCR5, a chemokine receptor used by HIV as a co …See details»

linkstock.net © 2022. All rights reserved